Professional
Added to YB: 2023-12-18
Pitch date: 2023-12-11
CTLT [bearish]
Catalent, Inc.
-68.2%
current return
Author Info
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide.
Market Cap
$11.5B
Pitch Price
$37.74
Price Target
N/A
Dividend
N/A
EV/EBITDA
31.44
P/E
-27.83
EV/Sales
3.65
Sector
Pharmaceuticals
Category
turnaround
Show full summary:
Accounting Red Flags Plague Catalent
$CTLT: Accounting red flags post-COVID as revenue quality declines. Premature revenue recognition, excess inventory, low R&D spend, SEC inquiries & insider selling signal aggressive accounting & potential headwinds. Strong Sell rating.
Read full article (24 min)